Weight loss outcomes similarly favor injectable formulations
Psychiatry 60 DabravolskiS
Trial registry Clinicaltrials.gov, Identifying number: NCT01720446, Date of registration: October 29, 2012 Similar content being viewed by others Background Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in people with type 2 diabetes (T2D) [1, 2], and diabetes itself confers a substantial independent risk of coronary heart disease, stroke, and death from other vascular causes [3]
However, it could reduce the risks of cardiovascular disease, cardiovascular, and overall mortality in patients with type 2 diabetes without viral hepatitis among Taiwan population
Hypotheses 143 , 110102 (2020)
NHS England and the Department of Health and Social Care have issued guidance prioritising existing patients and those with greatest clinical need